Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: respiratory disease therapy - Aphoenix

Next Previous
X
Search
Drug Profile

Research programme: respiratory disease therapy - Aphoenix

Alternative Names: AFX 002 series; AFX-300 series for respiratory disorders; Respiratory disease therapy research programme - Aphoenix

Latest Information Update: 04 Nov 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aphoenix
  • Class Small molecules
  • Mechanism of Action Chloride channel antagonists; Cytokine inhibitors; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Chronic obstructive pulmonary disease; Cystic fibrosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in Japan (PO)
  • 29 Jun 2005 This programme is still in active development for COPD - (BIO-2005)
  • 29 Jun 2005 No development reported - Preclinical for Cystic fibrosis in Japan (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top